SVB Leerink analyst Puneet Souda maintains Hologic (NASDAQ:HOLX) with a Outperform and raises the price target from $90 to $93.
Chemomab Wins New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent
